EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A case-control study of overall survival

Lung Cancer

Volumn 80, Issue 3, 2013, Pages 306-312

  Faehling, M ^a   Eckert, R ^b   Kamp, T ^b   Kuom, S ^a   Griese, U ^c   Strater J ^d   Ott, G ^c   Spengler, W ^e  

^a KLINIKUM ESSLINGEN   (Germany)

^b Onkologische Schwerpunktpraxis   (Germany)

^c ROBERT BOSCH HOSPITAL   (Germany)

^d Institut fur Pathologie   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Case control analysis; EGFR mutation; EGFR tyrosine kinase inhibitors; Erlotinib; NSCLC; Overall survival; Treatment failure

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEMCITABINE; LAPATINIB; METHOTREXATE; PEMETREXED; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SURVIVAL; CASE CONTROL STUDY; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LONG TERM CARE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; MUTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SKIN TOXICITY; SMOKING; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84877146688     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.02.010     Document Type: Article

References (33)

1. Silvestri G.A., Rivera M.P. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest 2005, 128:3975-3984.
2. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
3. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet 2008, 372:1809-1818.
4. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib of carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
5. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 24(362):2380-2388.
6. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label randomised phase 3 study. Lancet Oncol 2011, 12:735-742.
7. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
8. Chaft J.E., Oxnard G.R., Sima C.S., Kris M.G., Miller V.A., Riely G.J., et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011, 17:6298-6303.
9. Faehling M., Eckert R., Kuom S., Kamp T., Stoiber K.M., Schumann C. Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line. Oncology 2010, 78:249-258.
10. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144.
11. Sequist L.V. First-generation epidermal growth factor tyrosine kinase inhibitors in EGFR mutation positive non-small cell lung cancer patients. J Thorac Oncol 2008, 3:S143-S145.
12. Riely G.J., Kris M.G., Zhao B., Akhurst T., Milton D.T., Moore E., et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007, 13:5150-5155.
13. Taniguchi K., Okami J., Kodama K., Higashiyama M., Kato K. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 2008, 99:929-935.
14. Gazdar A.F. Activating and resistance mutations of EGFR in non-small cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009, 28:S24-S31.
15. von Minckwitz G., du Bois A., Schmidt M., Maass N., Cufer T., de Jongh F.E., et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 Study. J Clin Oncol 2009, 27:1999-2006.
16. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H., Sledge G., Koehler M., et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28:1124-1130.
17. Sharial M.S.N., Crown J., Hennessy B.T. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol 2012, 23:3007-3016.
18. Di Maio M., Lama N., Morabito A., Smit E.F., Georgoulias V., Takeda, et al. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer 2010, 46:735-743.
19. Bishoff H.G., van den Borne B., Pimentel F.L., Arellano J., Langer F., Leschinger M.I., et al. Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study). Curr Med Res Opin 2010, 26:1461-1470.
20. Li T., Ling Y.H., Goldman I.D., Perez-Soler R. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 2007, 1:3413-3422.
21. Giovannetti E., Lemos C., Tekle C., Smid K., Nannizzi S., et al. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 2008, 73:1290-1300.
22. Moore M.J., Goldstein D., Hamm J., Hamm J., Figer A., Hecht J.R., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-1966.
23. Ranson M., Reck M., Anthoney A., Hanauske A.R., Dean E., Melezinek I., et al. Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study. Ann Oncol 2010, 21:2233-2239.
24. Keedy V.L., Temin S., Somerfield M.R., Beasley M.B., Johnson D.H., McShane L.M., et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011, 29:2121-2127.
25. Becker A., Crombag L., Heideman D.A., Thunnissen F.B., van Wijk A.W., Postmus P.E., et al. Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur J Cancer 2011, 47:2603-2606.
26. Watanabe S., Tanaka J., Ota T., Kondo R., Tanaka H., Kagamu H., et al. Clinical responses to EGFR-tysosine kinase inhibitor retreatment in non-small-cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer 2011, 11:1.
27. Oh I.J., Ban H.J., Kim K.S., Kim Y.C. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study. Lung Cancer 2012, 77:121-127.
28. Inomata M., Shukuya T., Takahashi T., Ono A., Nakamura Y., Tsuya A., et al. Continuous administration EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer. Anticancer Res 2011, 31:4519-4523.
29. Shukuya T., Takahashi T., Naito T., Kaira R., Ono A., Nakamura Y., et al. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer 2011, 74:457-461.
30. Chen Y.J., Huang W.C., Wei Y.L., Hsu S.C., Yuan P., Lin H.Y., et al. Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS ONE 2011, 6:e21428.
31. Li T., Ling Y.H., Perez-Soler R. Tumor dependence on the EGFR signalling pathway expressed by the p-EGFR: p-AKT ratio predicts sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene. J Thoracic Oncol 2008, 3:643-647.
32. Zhu C.Q., da Cunha Santos G., Ding K., Sakurada A., Cutz J.C., Liu N., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26:4268-4275.
33. Nishino M., Cardarella S., Dahlberg S.E., Jackman D.M., Ramaiya N.H., Hatabu H., et al. Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer 2013, 79:283-288. Epub 2012 Dec 14. 10.1016/j.lungcan.2012.11.007.